BioOnco has expertise in the development and commercialization of immunoassays for accurate diagnosis. Our proprietary advanced diagnostic assays have been shown to be extremely useful, both for identifying the individuals infected with a specific viral or bacterial agent as well as those withcancer. These assays will introduce a simpler and faster test that has greater sensitivity and specificity at a reduced cost. In addition, these assays have also been used to monitor patient treatment. BioOnco efforts will be concentrated on marketing ELISA-based and rapid assays. These may utilize either antigens or antibodies. Assays under development include PSA(Prostate cancer), HIV(HIV-1/2 antibody and antigen detection).
